That being said, it is noteworthy that 62.1% of PCa patients in this study received at least one screening-based PSA, given that the study population consisted of individuals 68 or older to allow for ascertainment of receipt of PSA testing in the three years preceding their diagnosis. The gene discussed is KLK3; the disease is posterior cortical atrophy.